WCN24-2076 Proteonano™: a novel deep proteomics platform with 1000plex profiling capacity and picogram sensitivity and its application in diabetic kidney disease

The development of blood-based multi-biomarker panels for screening diabetic patients, and as an easy-to-access tool for identifying individuals at greatest risk of developing diabetic kidney disease (DKD) and its progression, is essential. However, conventional blood biomarker-based methodologies (e.g. clinical tests and ELISA) are unable to predict DKD progression with high sensitivity and specificity.